Skip to main content
. 2015 Jun;100(6):757–767. doi: 10.3324/haematol.2014.118497

Figure 1.

Figure 1.

CD9 expression is deregulated during PMF dysmegakaryopoiesis. (A) Expression of CD9 transcripts normalized to RPL38 by QRT-PCR in CD34+ cells from healthy donors (HD) and primary myelofibrosis (PMF) patients. (B) CD9 membrane expression (MFI) by flow cytometry on CD34+ cells purified from the peripheral blood (PB) of HD and PMF patients and CD9 membrane expression ranking (gray bars: PMF patients; white bars: HD). (C) Correlation between the CD9 membrane expression level on PMF CD34+ cells and the patient’s platelet count. (D) CD9 expression level on HD and PMF circulating platelets determined by flow cytometry (MFI). (E) Co-expression of CD9 and CD41 on PMF megakaryocytes derived from HD and PMF circulating CD34+ cells (D10 of culture). (F) Membrane expression analysis of CD9 on megakaryocytes (Mks) derived from CD34+ cells purified from the bone marrow (BM) or PB of HD and PMF patients (D10 of culture) by flow cytometry. (G) Western blot analysis and quantification of CD9 expression in Mks derived from circulating CD34+ cells from HD and PMF patients (D10 of culture).